Prediction of therapy response in ovarian cancer: Where are we now?
Identifieur interne : 000384 ( Main/Exploration ); précédent : 000383; suivant : 000385Prediction of therapy response in ovarian cancer: Where are we now?
Auteurs : Khalid El Bairi [Maroc] ; Mariam Amrani [Maroc] ; Abdul Hafeez Kandhro [Pakistan] ; Said Afqir [Maroc]Source :
- Critical reviews in clinical laboratory sciences [ 1549-781X ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Marqueurs biologiques.
- thérapie : Tumeurs de l'ovaire.
- épidémiologie : Tumeurs de l'ovaire.
- Femelle, Humains, Résultat thérapeutique, Valeur prédictive des tests.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Biomarkers.
- epidemiology : Ovarian Neoplasms.
- therapy : Ovarian Neoplasms.
- Female, Humans, Predictive Value of Tests, Treatment Outcome.
Abstract
Therapy resistance is a major challenge in the management of ovarian cancer (OC). Advances in detection and new technology validation have led to the emergence of biomarkers that can predict responses to available therapies. It is important to identify predictive biomarkers to select resistant and sensitive patients in order to reduce important toxicities, to reduce costs and to increase survival. The discovery of predictive and prognostic biomarkers for monitoring therapy is a developing field and provides promising perspectives in the era of personalized medicine. This review article will discuss the biology of OC with a focus on targetable pathways; current therapies; mechanisms of resistance; predictive biomarkers for chemotherapy, antiangiogenic and DNA-targeted therapies, and optimal cytoreductive surgery; and the emergence of liquid biopsy using recent studies from the Medline database and ClinicalTrials.gov.
DOI: 10.1080/10408363.2017.1313190
PubMed: 28443762
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000431
- to stream PubMed, to step Curation: 000430
- to stream PubMed, to step Checkpoint: 000412
- to stream Main, to step Merge: 000384
- to stream Main, to step Curation: 000384
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prediction of therapy response in ovarian cancer: Where are we now?</title><author><name sortKey="El Bairi, Khalid" sort="El Bairi, Khalid" uniqKey="El Bairi K" first="Khalid" last="El Bairi">Khalid El Bairi</name><affiliation wicri:level="1"><nlm:affiliation>a Faculty of Medicine and Pharmacy , Mohamed Ist University , Oujda , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>a Faculty of Medicine and Pharmacy , Mohamed Ist University , Oujda </wicri:regionArea><wicri:noRegion>Oujda </wicri:noRegion></affiliation></author><author><name sortKey="Amrani, Mariam" sort="Amrani, Mariam" uniqKey="Amrani M" first="Mariam" last="Amrani">Mariam Amrani</name><affiliation wicri:level="1"><nlm:affiliation>b Equipe de Recherche ONCOGYMA, Faculty of Medicine, Pathology Department , National Institute of Oncology, Université Mohamed V , Rabat , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>b Equipe de Recherche ONCOGYMA, Faculty of Medicine, Pathology Department , National Institute of Oncology, Université Mohamed V , Rabat </wicri:regionArea><wicri:noRegion>Rabat </wicri:noRegion></affiliation></author><author><name sortKey="Kandhro, Abdul Hafeez" sort="Kandhro, Abdul Hafeez" uniqKey="Kandhro A" first="Abdul Hafeez" last="Kandhro">Abdul Hafeez Kandhro</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Biochemistry , Healthcare Molecular and Diagnostic Laboratory , Hyderabad , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>c Department of Biochemistry , Healthcare Molecular and Diagnostic Laboratory , Hyderabad </wicri:regionArea><wicri:noRegion>Hyderabad </wicri:noRegion></affiliation></author><author><name sortKey="Afqir, Said" sort="Afqir, Said" uniqKey="Afqir S" first="Said" last="Afqir">Said Afqir</name><affiliation wicri:level="1"><nlm:affiliation>d Department of Medical Oncology , Mohamed VI University Hospital , Oujda , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>d Department of Medical Oncology , Mohamed VI University Hospital , Oujda </wicri:regionArea><wicri:noRegion>Oujda </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28443762</idno><idno type="pmid">28443762</idno><idno type="doi">10.1080/10408363.2017.1313190</idno><idno type="wicri:Area/PubMed/Corpus">000431</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000431</idno><idno type="wicri:Area/PubMed/Curation">000430</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000430</idno><idno type="wicri:Area/PubMed/Checkpoint">000412</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000412</idno><idno type="wicri:Area/Main/Merge">000384</idno><idno type="wicri:Area/Main/Curation">000384</idno><idno type="wicri:Area/Main/Exploration">000384</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prediction of therapy response in ovarian cancer: Where are we now?</title><author><name sortKey="El Bairi, Khalid" sort="El Bairi, Khalid" uniqKey="El Bairi K" first="Khalid" last="El Bairi">Khalid El Bairi</name><affiliation wicri:level="1"><nlm:affiliation>a Faculty of Medicine and Pharmacy , Mohamed Ist University , Oujda , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>a Faculty of Medicine and Pharmacy , Mohamed Ist University , Oujda </wicri:regionArea><wicri:noRegion>Oujda </wicri:noRegion></affiliation></author><author><name sortKey="Amrani, Mariam" sort="Amrani, Mariam" uniqKey="Amrani M" first="Mariam" last="Amrani">Mariam Amrani</name><affiliation wicri:level="1"><nlm:affiliation>b Equipe de Recherche ONCOGYMA, Faculty of Medicine, Pathology Department , National Institute of Oncology, Université Mohamed V , Rabat , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>b Equipe de Recherche ONCOGYMA, Faculty of Medicine, Pathology Department , National Institute of Oncology, Université Mohamed V , Rabat </wicri:regionArea><wicri:noRegion>Rabat </wicri:noRegion></affiliation></author><author><name sortKey="Kandhro, Abdul Hafeez" sort="Kandhro, Abdul Hafeez" uniqKey="Kandhro A" first="Abdul Hafeez" last="Kandhro">Abdul Hafeez Kandhro</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Biochemistry , Healthcare Molecular and Diagnostic Laboratory , Hyderabad , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>c Department of Biochemistry , Healthcare Molecular and Diagnostic Laboratory , Hyderabad </wicri:regionArea><wicri:noRegion>Hyderabad </wicri:noRegion></affiliation></author><author><name sortKey="Afqir, Said" sort="Afqir, Said" uniqKey="Afqir S" first="Said" last="Afqir">Said Afqir</name><affiliation wicri:level="1"><nlm:affiliation>d Department of Medical Oncology , Mohamed VI University Hospital , Oujda , Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>d Department of Medical Oncology , Mohamed VI University Hospital , Oujda </wicri:regionArea><wicri:noRegion>Oujda </wicri:noRegion></affiliation></author></analytic><series><title level="j">Critical reviews in clinical laboratory sciences</title><idno type="eISSN">1549-781X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomarkers (analysis)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Ovarian Neoplasms (epidemiology)</term><term>Ovarian Neoplasms (therapy)</term><term>Predictive Value of Tests (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Marqueurs biologiques (analyse)</term><term>Résultat thérapeutique (MeSH)</term><term>Tumeurs de l'ovaire (thérapie)</term><term>Tumeurs de l'ovaire (épidémiologie)</term><term>Valeur prédictive des tests (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Predictive Value of Tests</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Résultat thérapeutique</term><term>Valeur prédictive des tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Therapy resistance is a major challenge in the management of ovarian cancer (OC). Advances in detection and new technology validation have led to the emergence of biomarkers that can predict responses to available therapies. It is important to identify predictive biomarkers to select resistant and sensitive patients in order to reduce important toxicities, to reduce costs and to increase survival. The discovery of predictive and prognostic biomarkers for monitoring therapy is a developing field and provides promising perspectives in the era of personalized medicine. This review article will discuss the biology of OC with a focus on targetable pathways; current therapies; mechanisms of resistance; predictive biomarkers for chemotherapy, antiangiogenic and DNA-targeted therapies, and optimal cytoreductive surgery; and the emergence of liquid biopsy using recent studies from the Medline database and ClinicalTrials.gov.</div></front></TEI><affiliations><list><country><li>Maroc</li><li>Pakistan</li></country></list><tree><country name="Maroc"><noRegion><name sortKey="El Bairi, Khalid" sort="El Bairi, Khalid" uniqKey="El Bairi K" first="Khalid" last="El Bairi">Khalid El Bairi</name></noRegion><name sortKey="Afqir, Said" sort="Afqir, Said" uniqKey="Afqir S" first="Said" last="Afqir">Said Afqir</name><name sortKey="Amrani, Mariam" sort="Amrani, Mariam" uniqKey="Amrani M" first="Mariam" last="Amrani">Mariam Amrani</name></country><country name="Pakistan"><noRegion><name sortKey="Kandhro, Abdul Hafeez" sort="Kandhro, Abdul Hafeez" uniqKey="Kandhro A" first="Abdul Hafeez" last="Kandhro">Abdul Hafeez Kandhro</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000384 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000384 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= MaghrebDataLibMedV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28443762
|texte= Prediction of therapy response in ovarian cancer: Where are we now?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28443762" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MaghrebDataLibMedV2
| This area was generated with Dilib version V0.6.38. |  |